---
schema_version: "secwatch.filing_event.v1"
accession: "0001062822-24-000051"
form_type: "8-K"
ticker: "LXRX"
cik: "0001062822"
company_name: "LEXICON PHARMACEUTICALS, INC."
filed_at: "2024-09-16T23:59:59+00:00"
generated_at: "2026-05-31T04:28:37.074212+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lexicon Pharma CFO/COO Jeffrey Wade to depart Sep 30; Kristen Alexander named principal financial officer

## Summary
- Jeffrey Wade's employment as president, COO and principal financial officer terminates Sep 30, 2024.
- Wade receives salary continuation of $585k for 12 months, lump sum $175.5k, COBRA $3.7k/mo for 12 months, plus outplacement.
- Wade enters 8-month consulting agreement at $3,000/month starting after termination.
- Kristen Alexander, VP finance and accounting and principal accounting officer since 2021, becomes principal financial officer.

## SEC filing metadata
- accession: 0001062822-24-000051
- form_type: 8-K
- ticker: LXRX
- cik: 0001062822
- company_name: LEXICON PHARMACEUTICALS, INC.
- filed_at: 2024-09-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1062822/000106282224000051/0001062822-24-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1062822/000106282224000051/lxrx-20240913.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062822-24-000051
- JSON: https://secwatch.observer/filing/0001062822-24-000051.json
- Plain text: https://secwatch.observer/filing/0001062822-24-000051.txt

## Key facts
- Executive change
  Kristen L. Alexander was appointed as Principal Financial Officer at LEXICON PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Principal Financial Officer
  source text: Effective as of the date of termination of Mr. Wade’s employment, Kristen L. Alexander will assume the function of our principal financial officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1062822/000106282224000051/0001062822-24-000051-index.htm
- Executive change
  Jeffrey L. Wade was terminated as President and Chief Operating Officer at LEXICON PHARMACEUTICALS, INC..
  - Action: terminated
  - Role: President and Chief Operating Officer
  source text: On September 13, 2024, we and Jeffrey L. Wade determined that his employment as our president and chief operating officer (in which capacity, Mr. Wade has functioned as our principal financial officer) would terminate as of September 30, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1062822/000106282224000051/0001062822-24-000051-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.